The Innovation Center of Nanomedicine, Kawasaki Institute of Industrial Promotion (Director General: Kazunori Kataoka, Location: Kawasaki-ku Kawasaki City, Abbreviated name: iCONM) has started collaborative research with the Tokyo Metropolitan Institute of Medical Science (Director General: Hisao Masai, Location: Setagaya-ku, Tokyo, Abbreviated name: TMIMS). It aims to create technology for the rapid development of mRNA vaccine integrated with an adjuvant function to prepare for the recurrence of the new coronavirus (covid-19) and / or further mutated species of “coronavirus”.

The purpose of this collaborative research is to utilize the smart nanomachine®, which is the basic technology of iCONM, for the development technology of the recombinant vaccine possessed by TMIMS. It will develop the technology that enables efficient and inexpensive vaccine production, in shorter period of the time, to be prepared for the recurrence of the new coronavirus (covid-19) and / or further mutated species of “coronavirus”.

At the press conference held online on Thursday, June 4, Dr. Kazunori Kataoka (Director General, Innovation Center of Nanomedicine), Dr. Michinori Kohara (Project associate director, department of Microbiology and cell biology, Tokyo Metropolitan Institute of Medical Science), Dr. Satoshi Uchida (Visiting Scientist, Itaka Lab. Innovation Center of Nanomedicine) and spoke about the initiative and there was a deep discussion with journalists.